Eric Lo
1.4K posts

Eric Lo
@ericlhlo
Love technology, investment and macro views. Putting my energy to understand how things play out in the last mile 🤔





From my client post Tues: The Trade: Protection $MRVL $AMD $SMH $MU I also examine broader market conditions, investor positioning, and several macro factors that could influence stocks in the weeks ahead.

















Indonesia, from nothing, shoots up to No. 1 export market for BYD. Many going to Jakarta taxi fleets.




I have a super handsome 21yo Singaporean intern. Literally kpop handsome, since he was once approached by kpop scouts. He has like 100 IQ, but is emotionally quite intelligent. His EQ + handsomeness makes him insane at people-facing tasks. He can make any school girl grind her vocabulary. His aura makes rich moms hit on him and give him work just so they can keep him close and keep hitting. His major is actually media and I initially hired him to edit videos, but he sucks at it. I saw his potential and told him: Forget about your degree. Learn the craft of teaching with us. Marry a rich Singaporean girl and become a teacher.





In the next few months, four companies are raising over $350 billion in equity. – Google: $80B of net equity issuance to fund AI capex – SpaceX: ~$75B IPO at near-trillion valuation – Anthropic: raising at $965B post-money, up 53x from late 2024 – OpenAI: ~$100B at private market levels That's a third of a trillion in fresh paper supply from four names alone. Then there's the second wave. An Anthropic employee who joined in late 2024 with $100K of equity is sitting on roughly $5.3 million on paper today. There are thousands like them at Anthropic, OpenAI, SpaceX, Databricks, Stripe, xAI. Every single one is a future seller. At IPO, at lockup expiry, at the next tender. Founders, employees, and the earliest VCs are all trying to convert paper into cash at the same moment in history. When the people closest to the asset are all sellers at the same time, the question isn't whether the technology works. The question is who's left to be the bag holder. This is what an exit liquidity avalanche looks like. It doesn't crash a market in a day. It bleeds it for years.


Big wk for Chinese biotech firm Haisco (aka little HengRui). It not only scored a $3B out-licensing deal w/ Eli Lilly but also got its drug Cipepofol approved by FDA. The latter may be the big news here bc Chinese biotech firms had been out licensing drug from early stage to US big Pharma in order to cash out on their R&D. The US mkt has long FDA approval process w/ very stringent regulations, especially w/ clinical trials. Most Chinese biotech firms had been out-licensing to avoid this. We will see if this becomes more of a trend, since US mkt is heavily dependent on large Pharma sales network that keeps incumbent in charge.







